Document is current
Any future updates will be listed below
-
Authors
Iwuji, Collins
Waters, Laura
Milinkovic, Ana
Orkin, Chloe
Fox, Julie
Post, Frank
Perry, Nicky
Bruce, Chloe
Dailey, Natalie
To, Ye
Bremner, Stephen
Churchill, Duncan
Geretti, Anna Maria
-
Funding
Funding for this research was provided by:
Gilead Sciences (IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352, IN-UK-380-5352)
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 31 January 2025
First Online: 10 February 2025
Declarations
:
: The study was approved by the National Health Service Research Ethics Committee and the Health Research Authority (Ref: 19/LO/0905). Clinical Trial Authorisation was granted by the Medicine and Healthcare Products Regulatory Agency. All participants provided written informed consent prior to enrolment in the trial.
: Not applicable.
: C.I has received honoraria, support to attend conferences and research funding (paid to university of Sussex) from Gilead Sciences. AMG: reports personal fees from Abbott, Gilead, GSK, MSD, Roche, ViiV and research funding (to institution) from Gilead, Roche, ViiV. FP reports personal fees from Gilead Sciences, ViiV Healthcare/GlaxoSmithKline and MSD, and grants from Gilead Sciences, ViiV Healthcare/GlaxoSmithKline and MSD. LW has received speaker or advisory fees from ViiV, Janssen & Merck. She is an investigator on trials sponsored by Gilead, ViiV and Merck. C.O has received grants to her institution from Gilead, MSD ViiV, Janssen, Astra Zeneca. Travel Grants, honoraria and lecture fees from Gilead, MSD ViiV, Janssen, Bavarian nordic. J.F has received research grant from GSK paid to her institution and honorarium paid to her by ABBVIE.D.C; S.B; Y.T; N.D; C.B; Y.T; N.P: No conflict of interest to declare.
